中国P站

Pharmacogenomics; Cyp2c19 polymorphism; Clopidogrel resistance; Cardiovascular patients; Antiplatelet therapy; Genetic testing; Personalized medicine; Platelet reactivity; Genotype-guided therapy; Pharmacodynamic response

Introduction

Clopidogrel, a widely prescribed antiplatelet medication, plays a crucial role in preventing thrombotic events in patients undergoing percutaneous coronary interventions (PCI) or those with acute coronary syndromes (ACS). As a prodrug, clopidogrel requires metabolic activation by hepatic cytochrome P450 enzymes, particularly CYP2C19, to exert its antiplatelet effects [1-5]. However, significant interindividual variability in therapeutic response has been observed, with some patients displaying high on-treatment platelet reactivity, commonly referred to as clopidogrel resistance, which correlates with increased risk of recurrent cardiovascular events. Pharmacogenomics—the study of how genetic variations affect drug response—has identified CYP2C19 polymorphisms as a major contributor to clopidogrel variability. Loss-of-function alleles such as CYP2C19 *2 and 3 reduce the enzyme's ability to activate clopidogrel, while the gain-of-function 17 allele June increase drug activity. Given the growing evidence linking CYP2C19 genotype with clopidogrel efficacy and safety, there is increasing interest in genotype-guided antiplatelet therapy to optimize patient outcomes. This paper explores the pharmacogenomic landscape of CYP2C19 variants and their clinical implications in tailoring clopidogrel therapy among cardiovascular patients [6-10].

Discussion

Numerous clinical studies and meta-analyses have demonstrated a strong association between CYP2C19 loss-of-function alleles and poor response to clopidogrel. Patients carrying one or more reduced-function alleles have lower plasma concentrations of the active metabolite, leading to diminished platelet inhibition and increased incidence of adverse events such as stent thrombosis, myocardial infarction, and even cardiovascular mortality. Genotyping for CYP2C19 variants has thus emerged as a valuable tool in identifying patients at risk for poor clopidogrel response. In such cases, alternative antiplatelet agents such as prasugrel or ticagrelor, which do not rely heavily on CYP2C19 metabolism, June be more effective. Moreover, genotype-guided therapy has been shown to improve clinical outcomes by personalizing antiplatelet regimens. Real-world studies like the TAILOR-PCI and POPular Genetics trials have provided promising evidence supporting pharmacogenomic testing in routine care. However, implementation barriers remain, including cost, test turnaround time, and lack of physician awareness. In addition, the contribution of other genes (e.g., ABCB1, PON1) and non-genetic factors (e.g., drug interactions, comorbidities) must be considered when interpreting test results. Platelet function testing, though less specific than genotyping, June serve as a complementary approach. The development of clinical guidelines and decision-support tools is critical to integrate pharmacogenomics into daily cardiovascular practice effectively.

Conclusion

CYP2C19 polymorphisms significantly influence clopidogrel response and can impact clinical outcomes in cardiovascular patients. Genotype-guided antiplatelet therapy represents a major step toward personalized medicine, allowing clinicians to tailor treatment based on individual genetic profiles. While further studies are needed to refine dosing strategies and integrate multi-gene panels, the current body of evidence supports the use of pharmacogenomics in optimizing clopidogrel therapy. Overcoming practical barriers and expanding physician education will be essential to translate these insights into routine care. Ultimately, integrating CYP2C19 genotyping into cardiovascular therapy holds the potential to enhance treatment efficacy, reduce adverse events, and usher in a more precise, patient-centered approach to cardiovascular pharmacotherapy.

References

1.  
2. Allen TM, Cullis PR. (2004) . Science 303: 1818-1822.  

   , ,

3.  
4. Chakraborty C, Pal S, Doss GP, Wen Z, Lin C (2013) Frontiers in Bioscience 18: 1030-1050.  

   , ,

5.  
6. Langer R (1990) New methods of drug delivery. Science 249: 1527-1533.  

   , ,

7.  
8. Wolff JA (1990) . Science 247: 1465-1468.  

   , ,

9.  
10. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1991) Canadian Medical Association Journal 145: 1281-1286.  

    ,

11.  
12. Pickup J (1986) British Medical Journal 292: 155-157.  

    , ,

13.  
14. Edelstein ML, Abedi MR, Wixon J (2007) Journal of Gene Medicine 9: 833-842.  

    , ,

15.  
16. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J (2013) Journal of Gene Medicine 15: 65-77.  

    , ,

17.  
18. You Y, Lai X, Pan Y (2022) Signal Transduct Target Ther 7  

    , ,

19.  
20. Golriz Khatami S, Mubeen S, Bharadhwaj VS, Kodamullil AT, Hofmann-Apitius M, et al. (2021) NPJ Syst Biol Appl 7  

    , ,